Digital dose inhalers market seen topping $63.58B by 2030

The Business Research Company says the digital dose inhalers market is set for rapid growth, reaching $28.97 billion in 2026 and $63.58 billion by 2030. Rising asthma and COPD cases, along with demand for remote monitoring and medication adherence tools, are driving the outlook.

Why it matters: - Digital dose inhalers are moving from niche respiratory devices to a larger chronic-care technology category. - The market outlook points to strong demand for tools that improve dosing accuracy, medication adherence and remote monitoring. - Growth in asthma and COPD care gives the category a direct link to a large and expanding patient base.

What happened: - The Business Research Company released a report titled "Digital Dose Inhalers Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report estimates the market will rise from $23.78 billion in 2025 to $28.97 billion in 2026. - The report projects the market will reach $63.58 billion by 2030. - The company says the 2026-2030 growth rate will be 21.7% CAGR. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes a free sample and the full market report.

The details: - Digital dose inhalers use sensors and digital technology to track and monitor medication usage. - The devices deliver measured doses of medicine directly to the lungs. - The main patient groups are people with asthma and chronic obstructive pulmonary disease, or COPD. - The devices also provide real-time feedback and reminders to support adherence and disease management. - The report cites rising asthma and COPD prevalence, chronic respiratory disease burden, wider inhalation therapy use, expansion of hospital respiratory care and better access to inhaler medications as drivers of the 2025-2026 expansion. - The report cites demand for remote patient monitoring, personalized respiratory care, medication adherence, digital health ecosystems and higher chronic-disease spending as drivers of longer-term growth. - The report highlights smart inhalers, connected respiratory care technologies, home-based disease management and dose-tracking accuracy as major trends. - The Business Research Company says its 2026 reports include market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel forecasting dashboards, market-hotspot infographics and updated graphics and tables.

Between the lines: - The market thesis is less about the inhaler itself and more about data-enabled care around chronic lung disease. - The forecast suggests digital monitoring is becoming part of standard respiratory treatment, not just an add-on feature. - A US government agency, the National Center for Biotechnology Information, reported in December 2023 that COPD cases are expected to rise by 112 million to 592 million by 2050, equal to 9.5% of the eligible population. - That projection helps explain why connected devices for adherence and monitoring are attracting attention.

What's next: - The strongest near-term growth is expected in North America and then Asia-Pacific. - Product development is likely to keep focusing on connected features, usage tracking and home-care workflows. - Increased healthcare spending on chronic disease management could further support adoption through 2030.

The bottom line: - Digital dose inhalers are forecast to grow fast because respiratory care is shifting toward connected, measurable and home-friendly treatment models.